Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors

Biochemical Pharmacology

Volumn 73, Issue 2, 2007, Pages 259-269

  Engberg, Susanna ^a   Ahlstedt, Ingela ^a   Leffler, Agnes ^a   Lindström, Erik ^a   Kristensson, Elin ^a   Svensson, Arne ^a   Påhlman, Ingrid ^a   Johansson, Anders ^a   Drmota, Tomas ^a   von Mentzer, Bengt ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Gerbil; Gerbil foot tap; Homology models; Neurokinin 1 receptor cloning; Nueurokin receptor antagonists; Site directed mutagenesis

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; [2 (3,4 DICHLOROPHENYL) 4 [4 [2 (METHANESULFINYL)PHENYL]PIPERIDIN 1 YL]BUTYL]METHYLAMIDE; CALCIUM; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ A; NEUROKININ B; SUBSTANCE P; TRITIUM; ZD 6021;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; FOOT; GENE MUTATION; GERBIL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOBILIZATION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; DNA PRIMERS; GERBILLINAE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RATS; RECEPTORS, NEUROKININ-1; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 33845190308     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.09.030     Document Type: Article

References (47)

1. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and Erspamer V. The tachykinin peptide family. Pharm Rev 54 (2002) 285-322
2. Patacchini R., Lecci A., Holzer P., and Maggi C.A. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci 25 (2004) 1-3
3. Maggi C.A., Petacchini R., Rovero P., and Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Autonom Pharmacol 13 (1993) 23-93
4. Maggi C.A. Tachykinins in the autonomic nervous system. Pharm Res 33 (1996) 161-170
5. Pennefather J.N., Alessandro L., Candenas M.L., Patak E., Pinto F.M., and Maggi C.A. Tachykinins and tachykinin receptors: a growing family. Life Sci 74 (2004) 1445-1463
6. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for anti-depressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
7. Leroy V., Mauser P., Gao Z., and Peet N.P. Neurokinin receptor antagonists. Exp Opin Invest Drugs 9 (2000) 735-746
8. Holzer P., and Holzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol 1 6 (2001) 583-590
9. Lecci A., Valenti C., and Maggi C.A. Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Invest Drugs 3 (2002) 589-601
10. Duffy R.A. Potential therapeutic targets for neurokinin-1 receptor antagonists. Exp Opin Emerg Drugs 9 (2004) 9-21
11. Humphrey J.M. Medicinal chemistry of selective neurokinin antagonists. Curr Top Med Chem 3 (2003) 1423-1435
12. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 375 (1999) 51-60
13. Beresford I.J.M., Birch P.J., Hagan R.M., and Ireland S.J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol 104 (1991) 292-293
14. Appell K.C., Fragale B.J., Loscig J., Singh S., and Tomczuk B.E. Antagonists that demonstrate species differences in neurokinin-1 receptors. Mol Pharmacol 41 4 (1992) 772-778
15. Fong T.M., Yu H., and Strader C.D. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonist CP-96,345. J Biol Chem 267 (1992) 25668-25671
16. Sachais B.S., and Krause J.E. Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-1 receptor antagonist WIN 51708. J Pharmacol Exp Ther 46 (1994) 122-128
17. Sachais B.S., Snider R.M., Lowe J.A., and Krause J.E. Molecular basis for the species selectivity of the substance P antagonist CP-96,345. J Biol Chem 268 (1993) 2319-2323
18. Jensen C.J., Gerard N.P., Schwartz T.W., and Gether U. The species selectivity of chemically distinct tachykinin nonpeptide antagonists is dependent on common divergent residues of the rat and human neurokinin-1 receptors. Mol Pharmacol 45 2 (1994) 294-299
19. Pradier L., Habert-Ortoli E., Emile L., Le Guern J., Loquet I., Bock M.-D., et al. Molecular determinants of species selectivity of neurokinin type 1 receptor antagonists. Mol Pharmacol 47 (1995) 314-321
20. Bristow L.J., and Young L. Chromodacryorrhea and repitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. Eur J Pharmacol 253 (1994) 245-252
21. Rupniak N.M.J., Tattersall F.D., Williams A.R., Rycroft W., Carlson E.J., Cascieri M.A., et al. In vitro and in vivo predictors of the anti-emetic activity of tachylinin NK1 receptor antagonists. Eur J Pharmacol 326 (1997) 201-209
22. Rumsey W.L., Aharony D., Bialecki R.A., Abbott B.M., Barthlow H.G., Caccese R., et al. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors. J Pharmacol Exp Ther 298 (2001) 307-315
23. Megens A.A.H.P., Ashton D., Vermeire J.C.A., Vermonte P.C.M., Hens K.A., Hillen L.C., et al. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist. J Pharmacol Exp Ther 302 (2002) 696-709
24. Rupinak N., Carlsson E.J., Shepard S., Bentley G., Williams A.R., Hill A., et al. Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608. Neuropharmacology 45 (2003) 231-241
25. Duffy R.A., Varty G.B., Morgan C.A., and Lachowicz J.E. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioural effects of NK1 antagonists. J Pharmacol Exp Ther 301 (2002) 536-542
26. Varty G.B., Cohen-Williams M.E., Morgan C.A., Pylak U., Duffy R.A., Lachowicz J.E., et al. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27 (2002) 371-379
27. Varty G.B., Cohen-Williams M.E., and Hunter J.C. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 14 (2003) 87-95
28. Bernstein P.R., Aharony D., Albert J.S., Andisik D., Barthlow H.G., Bialecki R., et al. Discovery of novel, orally active dual NK1/NK2 antagonist. Bioorg Med Chem Lett 11 (2001) 2769-2773
29. Chandrasekhar S., and Mohanty P.K. Stereoselective synthesis of (+)-CP-99994: a substance P non-peptide antagonist. Tetrahedron Lett 40 (1999) 5071-5072
30. Peyronel A.T., Moutonnier C., and Garret C. Synthesis of RP-67,580, a new potent non-peptide substance P antagonist. Bioorg Med Chem Lett 2 (1992) 37-40
31. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248
32. Teller D.C., Okada T., Behnke C.A., Palczewski K., and Stenkamp R.E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 40 (2001) 7761-7772
33. i) and the concentration of inhibitor, which cause 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
34. Schwartz T.W. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5 (1994) 434-444
35. Evers A., and Klebe G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor. Based on a ligand-supported homology model. J Med Chem 47 (2004) 5381-5392
36. Fong T.M., Yu H., Cascieri M.A., Underwood D., Swain C.J., and Strader C.D. The role of histidine 265 in antagonist binding to the neurokinin-1 receptor. J Biol Chem 269 (1994) 2728-2732
37. Huang R.R.C., Yu H., Stocker C.D., and Fong T.M. Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. Biochemistry 33 (1994) 3007-3013
38. Lundström K., Hawcock A.B., Vargas A., Ward P., Thomas P., and Naylor A. Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity. Eur J Pharmacol 337 (1997) 73-81
39. Boks G.J., Tollenaere J.P., and Kroon J. Possible ligand-receptor interactions for NK1 antagonists as observed in their crystal structures. Bioorg Med Chem 5 (1997) 535-547
40. Swain C.J., Seward E.M., Cascieri M.A., Fong T.M., Herbert R., MacIntyre D.E., et al. Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane human NK1 antagonists. J Med Chem 38 (1995) 4793-4805
41. Elliott J.M., Cascieri M.A., Chicchi G., Davies S., Kelleher F.J., Kurtz M., et al. Serine derived NK1 antagonists. 1. The effect of modifications to the serine substituents. Bioorg Med Chem Lett 8 (1998) 1845-1850
42. Elliott J.M., Broughton H., Cascieri M.A., Chicchi G., Huscroft I.T., Kurtz M., et al. Serine derived NK1 antagonists. 2. A pharmacophore model for arylsulfonamide binding. Bioorg Med Chem Lett 8 (1998) 1851-1856
43. Takeuchi Y., Shands E.F.B., Beusen D.D., and Marshall G.R. Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor. J Med Chem 41 (1998) 3609-3623
44. Jacoby E., Boudon A., Kucharczyk N., Michel A., and Fauchere J.L. A structural rationale for the design of water soluble peptide-derived neurokinin-1 antagonists. J Recep Signal Transduction Res 17 (1997) 855-873
45. Vedani A., Briem H., Dobler M., Dollinger H., and McMasters D.R. Multiple-conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. J Med Chem 43 (2000) 4416-4427
46. Poulsen A., Björholm B., Gundetofte K., Pogozheva I.D., and Liljefors T. Pharmacophore and receptor models for neurokinin receptors. J Comput-Aided Mol Design 17 (2003) 765-783
47. Poulsen, Bjornholm B., Gundertofte K., Pogozheva I.D., and Liljefors T. Pharmacophore and receptor models for neurokinin receptors. J Computer-Aided Mol Design 17 11 (2004) 765-783